Long Term Follow up Investigation of Endobronchial Valves in Emphysema
Launched by PULMONX INTERNATIONAL SÀRL · Apr 17, 2012
Trial Information
Current as of September 10, 2025
Terminated
Keywords
ClinConnect Summary
Primary objective is pulmonary function as assessed by FEV1 and secondary objectives are health related quality of life as assessed by the modified MRC dyspnea score and by the COPD assessment test, and survival at five years. 2000 patients will be enrolled in the study from approximately 200 referring centres in Germany. Patients will be followed up at 3, 6, and 12 months, and then yearly up to 5 years. The study will observe normal clinical practice. No investigations beyond those performed in normal clinical practice will be required with the exception of two short questionnaires. Patien...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients of both genders of at least 18 years of age
- • Understand and voluntarily sign an informed consent form.
- • FEV1 \> 15% predicted and \< 45% predicted
- • RV \>180% predicted
- • Diagnosis of emphysema with CT evidence of hyperinflation . Absence of collateral ventilation according to Chartis Assessment System
- Exclusion Criteria:
- • • Active pulmonary infection
About Pulmonx International Sàrl
Pulmonx International Sàrl is a leading medical technology company focused on advancing innovative solutions for patients with respiratory diseases, particularly those with chronic obstructive pulmonary disease (COPD) and other lung conditions. With a commitment to improving patient outcomes, Pulmonx develops and commercializes minimally invasive therapies, including its proprietary Zephyr® Endobronchial Valve system, designed to enhance lung function and quality of life. The company is dedicated to rigorous clinical research and collaboration with healthcare professionals, striving to push the boundaries of pulmonary care through cutting-edge technology and evidence-based practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Heidelberg, Germany
Patients applied
Trial Officials
Felix JF Herth, Prof. Dr.
Principal Investigator
Medizinische Fakultät Heidelberg
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials